Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EBV Positive Mutation Tumor”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Looking for participantsNCT04260022
What this trial is testing

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Who this might be right for
Leukemia, Myeloid, ChronicMyeloid LeukemiaChronic Myeloid Leukemia+2 more
Ascentage Pharma Group Inc. 242
Testing effectiveness (Phase 2)Looking for participantsNCT06239272
What this trial is testing

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Who this might be right for
Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more
St. Jude Children's Research Hospital 139
Testing effectiveness (Phase 2)UnknownNCT03491345
What this trial is testing

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Who this might be right for
PD-L1 Positive Mutation TumorEBV Positive Mutation TumorMSI-H Mutation Tumor+1 more
Yonsei University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT02143414
What this trial is testing

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+2 more
National Cancer Institute (NCI) 53